Free Shipping on All Orders $75 Or More! Ends January 31st.

Your Trusted Brand for Over 35 Years

Life Extension Magazine

<< Back to August 2014

Safely Manage Menopausal Symptoms

August 2014

By Alicia Nadil

How To Measure Breast Cancer Risk

How To Measure Breast Cancer Risk  

Of special importance, a recent study demonstrated that when HMR lignan is combined with indole-3-carbinol, a beneficial compound in broccoli and other cruciferous vegetables,41 it produces a vital shift in the ways that natural estrogen is metabolized in a woman’s body.42

Although estrogen is a natural hormone produced by both women and men, it undergoes chemical changes through the actions of enzymes in the liver. One of those enzyme systems produces so-called 2-hydroxy estrogen breakdown products, while the other produces 16-hydroxy versions of the molecule.43 The 2-hydroxy version appears to offer protection against breast cancer,44 while the 16-hydroxy version remains powerful enough to raise a woman’s chances of developing breast cancer.45 The ratio of 2-hydroxy to 16-hydroxy molecules is therefore a good measure of a woman’s breast cancer risk, with the higher the ratio (meaning more beneficial 2-hydroxy and less dangerous 16-hydroxy), the lower her risk.43,46 In the recent study, a breast health nutritional formula containing HMR lignan plus indole-3-carbinol was shown to be capable of shifting estrogen metabolism toward the 2-hydroxy version and raising the 2:16-hydroxy ratio; an important step in minimizing the risk of breast (and possibly other) cancers.42 This is in line with other studies demonstrating that consumption of cruciferous vegetables nudges the 2:16-hydroxy ratio in a direction that favors protection from breast cancers.45,47

Summary

Replacing estrogen lost to menopause was once relegated to taking unnatural-to-the-body estrogen drugs and dangerous synthetic progestins (which is not the same as progesterone). These pharmaceutical approaches are declining as maturing women insist on natural hormone replacement protocols.

Treatment with plant-derived, estrogen-like molecules called phytoestrogens and natural progesterone are showing great promise in relieving symptoms of the menopausal transition and at restoring some of the protection enjoyed by premenopausal women against cancer and other chronic conditions.55

Extracts of hops and Norway spruce are rich in such phytoestrogens, as well as in other molecules that protect women against low-estrogen-induced conditions. These molecules have now been studied and appear to lead the field in the combination of symptom relief and protective effects.

Additional plant extracts, many of them in use for centuries in traditional medical systems, can add further symptomatic relief and disease-preventive effects. These natural plant derivatives are increasingly being made available in convenient combination formulations.54

If you have any questions on the scientific content of this article, please call a Life Extension® Health Advisor at 1-866-864-3027.

References

  1. Menati L, Khaleghinezhad K, Tadayon M, Siahpoosh A. Evaluation of contextual and demographic factors on licorice effects on reducing hot flashes in postmenopause women. Health Care Women Int. 2014 Jan;35(1):87-99.
  2. Nahidi F, Zare E, Mojab F, Alavi-Majd H. Effects of licorice on relief and recurrence of menopausal hot flashes. Iran J Pharm Res. 2012 Spring;11(2):541-8.
  3. Stephenson K, Neuenschwander PF, Kurdowska AK. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women. Int J Pharm Compd. 2013 Jan-Feb;17(1):74-85.
  4. Freeman EW, Sammel MD, Sanders RJ. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause. 2014 Jan 27. [Epub ahead of print]
  5. Harlow SD, Paramsothy P.Menstruation and the menopausal transition. Obstet Gynecol Clin North Am. 2011 Sep;38(3):595-607.
  6. Lobo RA. Menopause and stroke and the effects of hormonal therapy. Climacteric. 2007 Oct;10 Suppl 2:27-31.
  7. Kreatsoulas C, Anand SS. Menopausal hormone therapy for the primary prevention of chronic conditions. U.S. Preventive Services Task Force recommendation statement. Pol Arch Med Wewn. 2013;123(3):112-7.
  8. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002 Jul 17;288(3):321-33.
  9. Tit DA, Lazar L, Bungau S, Pallag A, Bei D. The evaluation of the effectiveness of phytoestrogens in improving, reduction or suppression of the climacteric symptomatology. Studia Universitatis “Vasile Goldis” Seria Stiintele Vietil. 2013; 23(4):585-96.
  10. Overk CR, Yao P, Chadwick LR, et al. Comparison of the in vitro estrogenic activities of compounds from hops (Humulus lupulus) and red clover (Trifolium pratense). J Agric Food Chem. 2005 Aug 10;53(16):6246-53.
  11. Hemachandra LP, Madhubhani P, Chandrasena R, et al. Hops (Humulus lupulus) inhibits oxidative estrogen metabolism and estrogen-induced malignant transformation in human mammary epithelial cells (MCF-10A). Cancer Prev Res (Phila). 2012 Jan;5(1):73-81.
  12. Overk CR, Guo J, Chadwick LR, et al. In vivo estrogenic comparisons of Trifolium pratense (red clover) Humulus lupulus (hops), and the pure compounds isoxanthohumol and 8-prenylnaringenin. Chem Biol Interact. 2008 Oct 22;176(1):30-9.
  13. Stansbury J, Saunders PR, Winston D. The safety of phytoestrogens in menopause, prostate and breast cancer. Journal of Restorative Medicine. 2013; 2(1), 101-8.
  14. Possemiers S, Verstraete W. Oestrogenicity of prenylflavonoids from hops: activation of pro-oestrogens by intestinal bacteria. Environ Microbiol Rep. 2009 Apr;1(2):100-9.
  15. Stevens JF, Page JE. Xanthohumol and related prenylflavonoids from hops and beer: to your good health! Phytochemistry. 2004 May;65(10):1317-30.
  16. Oberbauer E, Urmann C, Steffenhagen C, et al. Chroman-like cyclic prenylflavonoids promote neuronal differentiation and neurite outgrowth and are neuroprotective. J Nutr Biochem. 2013 Nov;24(11):1953-62.
  17. Keiler AM, Zierau O, Kretzschmar G. Hop extracts and hop substances in treatment of menopausal complaints. Planta Med. 2013 May;79(7):576-9.
  18. Cosentino M, Marino F, Ferrari M, et al. Estrogenic activity of 7-hydroxymatairesinol potassium acetate (HMR/lignan) from Norway spruce (Picea abies) knots and of its active metabolite enterolactone in MCF-7 cells. Pharmacol Res. 2007 Aug;56(2):140-7.
  19. Milligan SR, Kalita JC, Heyerick A, Rong H, De Cooman L, De Keukeleire D. Identification of a potent phytoestrogen in hops (Humulus lupulus L.) and beer. J Clin Endocrinol & Metabol. 1999;84:6:2249.
  20. Nagel J, Culley LK, Lu Y, Liu E, Matthews PD, Stevens JF,Page JE. EST analysis of hop glandular trichomes identifies an O-methyltransferase that catalyzes the biosynthesis of xanthohumol. The Plant Cell Online. 2008; 20(1), 186-200.
  21. Dietz BM, Hagos GK, Eskra JN, et al. Differential regulation of detoxification enzymes in hepatic and mammary tissue by hops (Humulus lupulus) in vitro and in vivo. Mol Nutr Food Res. 2013 Jun;57(6):1055-66.
  22. Rimoldi G, Christoffel J, Wuttke W. Morphologic changes induced by oral long-term treatment with 8-prenylnaringenin in the uterus, vagina, and mammary gland of castrated rats. Menopause. 2006 Jul-Aug;13(4):669-77.
  23. Bolca S, Possemiers S, Maervoet V, et al. Microbial and dietary factors associated with the 8-prenylnaringenin producer phenotype: a dietary intervention trial with fifty healthy post-menopausal Caucasian women. Br J Nutr. 2007 Nov;98(5):950-9.
  24. Rad M, Humpel M, Schaefer O, et al. Pharmacokinetics and systemic endocrine effects of the phyto-oestrogen 8-prenylnaringenin after single oral doses to postmenopausal women. Br J Clin Pharmacol. 2006 Sep;62(3):288-96.
  25. Bowe J, Li XF, Kinsey-Jones J, et al. The hop phytoestrogen, 8-prenylnaringenin, reverses the ovariectomy-induced rise in skin temperature in an animal model of menopausal hot flushes. J Endocrinol. 2006 Nov;191(2):399-405.
  26. Heyerick A, Vervarcke S, Depypere H, Bracke M, De Keukeleire D. A first prospective, randomized, double-blind, placebo-controlled study on the use of a standardized hop extract to alleviate menopausal discomforts. Maturitas. 2006 May 20;54(2):164-75.
  27. Erkkola R, Vervarcke S, Vansteelandt S, Rompotti P, De Keukeleire D, Heyerick A. A randomized, double-blind, placebo-controlled, cross-over pilot study on the use of a standardized hop extract to alleviate menopausal discomforts. Phytomedicine. 2010 May;17(6):389-96.
  28. Yuan Y, Qiu X, Nikolic D, et al. Inhibition of human cytochrome P450 enzymes by hops (Humulus lupulus) and hop prenylphenols. Eur J Pharm Sci. 2014 Mar 12;53:55-61.
  29. Allsopp P, Possemiers S, Campbell D, Gill C, Rowland I. A comparison of the anticancer properties of isoxanthohumol and 8-prenylnaringenin using in vitro models of colon cancer. Biofactors. 2013 Jul-Aug;39(4):441-7.
  30. Blanquer-Rossello MM, Oliver J, Valle A, Roca P. Effect of xanthohumol and 8-prenylnaringenin on MCF-7 breast cancer cells oxidative stress and mitochondrial complexes expression. J Cell Biochem. 2013 Dec;114(12):2785-94.
  31. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B, Sinclair DA. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 2003 Sep 11;425(6954):191-6.
  32. 32.Mukai R, Horikawa H, Fujikura Y, et al. Prevention of disuse muscle atrophy by dietary ingestion of 8-prenylnaringenin in denervated mice. PLoS One. 2012;7(9):e45048.
  33. Saarinen NM, Warri A, Makela SI, et al. Hydroxymatairesinol, a novel enterolactone precursor with antitumor properties from coniferous tree (Picea abies). Nutr Cancer. 2000;36(2):207-16.
  34. Heinonen S, Nurmi T, Liukkonen K, et al. In vitro metabolism of plant lignans: new precursors of mammalian lignans enterolactone and enterodiol. J Agric Food Chem. 2001 Jul;49(7):3178-86.
  35. Saarinen NM, Penttinen PE, Smeds AI, Hurmerinta TT, Makela SI. Structural determinants of plant lignans for growth of mammary tumors and hormonal responses in vivo. J Steroid Biochem Mol Biol. 2005 Feb;93(2-5):209-19.
  36. Saarinen NM, Huovinen R, Warri A, et al. Uptake and metabolism of hydroxymatairesinol in relation to its anticarcinogenicity in DMBA-induced rat mammary carcinoma model. Nutr Cancer. 2001;41(1-2):82-90.
  37. Udani JK, Brown DJ, Tan MO, Hardy M. Pharmacokinetics and bioavailability of plant lignan 7-hydroxymatairesinol and effects on serum enterolactone and clinical symptoms in postmenopausal women: a single-blinded, parallel, dose-comparison study. J Am Coll Nutr. 2013 Dec;32(6):428-35.
  38. Miura D, Saarinen NM, Miura Y, Santti R, Yagasaki K. Hydroxymatairesinol and its mammalian metabolite enterolactone reduce the growth and metastasis of subcutaneous AH109A hepatomas in rats. Nutr Cancer. 2007;58(1):49-59.
  39. Cosentino M, Marino F, Maio RC, et al. Immunomodulatory activity of the lignan 7-hydroxymatairesinol potassium acetate (HMR/lignan) extracted from the heartwood of Norway spruce (Picea abies). Int Immunopharmacol. 2010 Mar;10(3):339-43.
  40. Lina B, Korte H, Nyman L, Unkila M. A thirteen week dietary toxicity study with 7-hydroxymatairesinol potassium acetate (HMRlignan) in rats. Regul Toxicol Pharmacol. 2005 Feb;41(1):28-38.
  41. Chen Z, Tao ZZ, Chen SM, Chen C, Li F, Xiao BK. Indole-3-carbinol inhibits nasopharyngeal carcinoma growth through cell cycle arrest in vivo and in vitro. PLoS One. 2013 Dec 16;8(12):e82288.
  42. Laidlaw M, Cockerline CA, Sepkovic DW. Effects of a breast-health herbal formula supplement on estrogen metabolism in pre- and post-menopausal women not taking hormonal contraceptives or supplements: a randomized controlled trial. Breast Cancer (Auckl). 2010;4:85-95.
  43. Bradlow HL, Telang NT, Sepkovic, DW, Osborne MP. 2-hydroxyestrone: the’good’estrogen. Journal of Endocrinology. 1996;150(3 Suppl), S259-S265.
  44. Ho GH, Luo XW, Ji CY, Foo SC, Ng EH. Urinary 2/16 alpha-hydroxyestrone ratio: correlation with serum insulin-like growth factor binding protein-3 and a potential biomarker of breast cancer risk. Ann Acad Med Singapore. 1998 Mar;27(2):294-9.
  45. Fowke JH, Longcope C, Hebert JR. Brassica vegetable consumption shifts estrogen metabolism in healthy postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2000 Aug;9(8):773-9.
  46. Kabat GC, O’Leary ES, Gammon MD, et al. Estrogen metabolism and breast cancer. Epidemiology. 2006 Jan;17(1):80-8.
  47. Dalessandri KM, Firestone GL, Fitch MD, Bradlow HL, Bjeldanes LF. Pilot study: effect of 3,3’-diindolylmethane supplements on urinary hormone metabolites in postmenopausal women with a history of early-stage breast cancer. Nutr Cancer. 2004;50(2):161-7.
  48. Ambrosone CB, McCann SE, Freudenheim JL, Marshall JR, Zhang Y, Shields PG. Breast cancer risk in premenopausal women is inversely associated with consumption of broccoli, a source of isothiocyanates, but is not modified by GST genotype. J Nutr. 2004 May;134(5):1134-8.
  49. Circosta C, Pasquale RD, Palumbo DR, Samperi S, Occhiuto F. Estrogenic activity of standardized extract of Angelica sinensis. Phytother Res. 2006 Aug;20(8):665-9.
  50. Mazaro-Costa R, Andersen ML, Hachul H, Tufik S. Medicinal plants as alternative treatments for female sexual dysfunction: utopian vision or possible treatment in climacteric women? J Sex Med. 2010 Nov;7(11):3695-714.
  51. Lucks BC. Vitex agnus castus essential oil and menopausal balance: a research update [Complementary Therapies in Nursing and Midwifery 8 (2003) 148-154]. Complement Ther Nurs Midwifery. 2003 Aug;9(3):157-60.
  52. Lucks BC, Sorensen J, Veal L. Vitexagnus-castus essential oil and menopausal balance: a self-care survey. Complement Ther Nurs Midwifery. 2002 Aug;8(3):148-54.
  53. Liu J, Burdette JE, Xu H, et al. Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. J Agric Food Chem. 2001 May;49(5):2472-9.
  54. Hess R, Thurston RC, Hays RD, Chang CCH, Dillon SN, Ness RB, et al. The impact of menopause on health-related quality of life: results from the STRIDE longitudinal study. Quality of Life Research. 2012; 21(3), 535-544.
  55. Wiseman H. The therapeutic potential of phytoestrogens. Expert Opin Investig Drugs. 2000 Aug;9(8):1829-40.
  56. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet. 1997 Oct 11;350(9084):1047-59.
  57. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013 Oct 2;310(13):1353-68.